Results 11 to 20 of about 222,697 (389)

Platelet aggregation inhibitors from hematophagous animals [PDF]

Toxicon, 2010
Salivary glands from blood-sucking animals (e.g., mosquitoes, bugs, sand flies, fleas, ticks, leeches, hookworms, bats) are a rich source of bioactive molecules that counteract hemostasis in a redundant and synergistic manner. This review discusses recent progress in the identification of salivary inhibitors of platelet aggregation, their molecular ...
I. Francischetti
openaire   +3 more sources

Platelet Aggregation Inhibitors [PDF]

Encyclopedia of Molecular Pharmacology, 2021
semanticscholar   +4 more sources

The Periprocedural Management of Anticoagulation and Platelet Aggregation Inhibitors in Endoscopic Interventions. [PDF]

Dtsch Arztebl Int, 2016
Lange CM, Fichtlscherer S, Miesbach W, Zeuzem S, Albert J.   +4 more
europepmc   +2 more sources

Inhibition of platelet aggregation by protease inhibitors. Possible involvement of proteases in platelet aggregation [PDF]

Blood, 1978
Abstract The possible participation of proteases in human platelet aggregation was explored using various protease inhibitors and substrates. Protease inhibitors used included naturally occurring inhibitors of serine proteases and synthetic inhibitors that modify the active site of protease.
N, Aoki, K, Naito, N, Yoshida
openaire   +4 more sources

Oral Bruton tyrosine kinase inhibitors block activation of the platelet Fc receptor CD32a (FcγRIIA): a new option in HIT?

Blood Advances, 2019
: Activation of the platelet Fc-receptor CD32a (FcγRIIA) is an early and crucial step in the pathogenesis of heparin-induced thrombocytopenia type II (HIT) that has not been therapeutically targeted.
Luise Goldmann, Rundan Duan, Thorsten Kragh, Georg Wittmann, Christian Weber, Reinhard Lorenz, Philipp von Hundelshausen, Michael Spannagl, Wolfgang Siess   +8 more
doaj   +2 more sources

Platelet Aggregation Inhibitors. I. Hydroxylamine: A Potent Inhibitor of Platelet Aggregation

Chemical and Pharmaceutical Bulletin, 1972
K, Iizuka, K, Kikugawa
openaire   +4 more sources

The perioperative management of treatment with anticoagulants and platelet aggregation inhibitors. [PDF]

Dtsch Arztebl Int, 2013
Schlitt A, Jámbor C, Spannagl M, Gogarten W, Schilling T, Zwissler B.   +5 more
europepmc   +2 more sources

The search of compounds with antiaggregation activity among S-esters of thiosulfonic acids [PDF]

The Ukrainian Biochemical Journal, 2015
According to the current understanding, the hyperactivation of platelets may lead to increased intravascular coagulation and thrombosis. Today a relevant issue is the search for new anti-thrombotic agents that are able to modulate the activity of ...
T. I. Halenova, I. V. Nikolaeva, A. V. Nakonechna, K. B. Bolibrukh, N. Y. Monka, V. I. Lubenets, O. M. Savchuk, V. P. Novikov, L. I. Ostapchenko   +8 more
doaj   +1 more source

Low-dose and standard-dose ticagrelor compared with clopidogrel in patients with acute coronary syndromes: A cohort study from china

Frontiers in Cardiovascular Medicine, 2022
PurposePrevious trials have demonstrated that ticagrelor was superior to clopidogrel in acute coronary syndrome (ACS) patients. However, several recent studies showed that ticagrelor was associated with a significantly higher risk of bleeding compared ...
Wenxing Peng, Yunnan Zhang, Yunnan Zhang, Yang Lin   +3 more
doaj   +1 more source

Paradigm of biased PAR1 (protease-activated receptor-1) activation and inhibition in endothelial cells dissected by phosphoproteomics [PDF]

, 2017
Thrombin is the key serine protease of the coagulation cascade and mediates cellular responses by activation of PARs (protease-activated receptors). The predominant thrombin receptor is PAR1, and in endothelial cells (ECs), thrombin dynamically regulates
Hoogendijk, Arie J., Meijer, Alexander B., Mertens, Koen, Simpson, Pelle J., van Alphen, Floris P.J., van den Biggelaar, Maartje, van den Eshof, Bart L., Zanivan, Sara   +7 more
core   +5 more sources